CD47 'don't eat me' signal in CML
Part of Blood & lymphatic, Cancer clinical trials.
This study is looking at a marker called CD47 (sometimes called a 'don't eat me' signal) in people with Chronic Myeloid Leukemia (CML). The goal is to understand how CD47 might affect the disease and find new ways to treat it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with Chronic Myeloid Leukemia (CML) based on the 2022 WHO guidelines.
- You do NOT have another blood cancer like ALL, CLL, or plasma cell myeloma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at two markers (CD38 and CD56) on cells from people with chronic myeloid leukemia (CML). It may help doctors understand the disease better and could guide treatment choices in the future.
This trial is a real-life study that collects information from people living with chronic myeloid leukemia (CML). It may help doctors understand how CML treatments are used in practice and how well they work over time.
This trial is testing a new, highly sensitive blood test (digital PCR) to find BCR::ABL1 mutations in people with chronic-phase CML who are switching their tyrosine kinase inhibitor (TKI) because of resistance or a warning sign. The goal is to see if this test can help guide treatment decisions more precisely.
This study looks at two proteins on cancer cells (CD305 and CD85d) to better understand types of B-cell blood cancers. Results may help doctors tailor future treatments.
This trial looks at a marker called CD56 in people who have been newly diagnosed with a blood cancer (a hematologic malignancy). The results may help doctors better understand the disease and guide future treatment choices.
This study looks at how your 'biological age' (how old your body seems) affects how well you do on targeted therapy for chronic myeloid leukemia. It aims to personalize your care by combining age and frailty information.
Hear when a new Chronic Myeloid Leukemia (CML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.